Aridis Pharmaceuticals logo
Aridis Pharmaceuticals ARDS

Quarterly report 2023-Q3
added 11-06-2023

report update icon

Aridis Pharmaceuticals Accounts Receivables 2011-2026 | ARDS

Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.
Examples of accounts receivable
  • Customers have not paid invoices for delivered products
  • An advance has been paid to a supplier, but goods have not yet been received
  • Employees have not reported on accountable amounts
  • The government must refund tax overpayments
  • Outstanding loans issued
Importance of accounts receivable in company analysis
  1. Asset quality
    Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment.
  2. Impact on cash flow
    Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages.
  3. Assessment of management efficiency
    The following accounts receivable turnover ratios are commonly used:
    Receivables turnover = Revenue / Average accounts receivable
    (the higher — the better)

    Days Sales Outstanding (DSO) = 365 / Turnover
    (the fewer days — the faster customers pay)

    If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.

Annual Accounts Receivables Aridis Pharmaceuticals

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
1 M - - - 1.66 M - - - - - - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
1.66 M 1 M 1.33 M

Quarterly Accounts Receivables Aridis Pharmaceuticals

2023-Q3 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1
417 K 1 M - 1 M - - 1 M - - - - - - - - - - 1.66 M 1.66 M 1.66 M 1.66 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Indicator range from quarterly reporting

Maximum Minimum Average
1.66 M 417 K 1.26 M

Accounts Receivables of other stocks in the Biotechnology industry

Issuer Accounts Receivables Price % 24h Market Cap Country
Agenus Agenus
AGEN
800 K $ 3.27 -1.8 % $ 1.17 M usaUSA
Agios Pharmaceuticals Agios Pharmaceuticals
AGIO
3.43 M $ 29.33 -2.98 % $ 1.7 B usaUSA
I-Mab I-Mab
IMAB
130 M - - $ 866 M chinaChina
Akebia Therapeutics Akebia Therapeutics
AKBA
47 M $ 1.26 -3.44 % $ 324 M usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
57 K - -10.17 % $ 12.2 K usaUSA
Alkermes plc Alkermes plc
ALKS
334 M $ 29.32 -2.61 % $ 4.83 B irlandaIrlanda
Alnylam Pharmaceuticals Alnylam Pharmaceuticals
ALNY
778 M $ 330.95 -0.59 % $ 43.4 B usaUSA
Altimmune Altimmune
ALT
544 K $ 4.2 -2.55 % $ 298 M usaUSA
Amgen Amgen
AMGN
9.57 B $ 387.85 0.03 % $ 209 B usaUSA
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
144 M $ 20.22 -0.05 % $ 945 M usaUSA
Amarin Corporation plc Amarin Corporation plc
AMRN
134 M $ 13.62 -1.3 % $ 5.55 B irlandaIrlanda
AIM ImmunoTech AIM ImmunoTech
AIM
34 K $ 0.92 5.25 % $ 44.2 M usaUSA
AnaptysBio AnaptysBio
ANAB
40.8 M $ 54.61 -0.8 % $ 1.55 B usaUSA
Anika Therapeutics Anika Therapeutics
ANIK
36 M $ 14.44 0.53 % $ 212 M usaUSA
ANI Pharmaceuticals ANI Pharmaceuticals
ANIP
222 M $ 75.31 1.91 % $ 1.45 B usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
17.3 M - -24.86 % $ 820 K usaUSA
Acasti Pharma Acasti Pharma
ACST
802 K - 4.01 % $ 150 M canadaCanada
Adverum Biotechnologies Adverum Biotechnologies
ADVM
886 K - - $ 86.2 M usaUSA
Apellis Pharmaceuticals Apellis Pharmaceuticals
APLS
366 M $ 20.53 -2.05 % $ 2.59 B usaUSA
Aptorum Group Limited Aptorum Group Limited
APM
62.2 K $ 0.78 -0.67 % $ 4.25 M chinaChina
AIkido Pharma AIkido Pharma
AIKI
200 K - 1.93 % $ 17.4 M usaUSA
Aptevo Therapeutics Aptevo Therapeutics
APVO
5.22 M $ 7.28 -0.55 % $ 2.01 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
3.27 M - -0.23 % $ 916 M usaUSA
Aquestive Therapeutics Aquestive Therapeutics
AQST
7.34 M $ 3.99 -0.15 % $ 346 M usaUSA
Arcturus Therapeutics Holdings Arcturus Therapeutics Holdings
ARCT
3.97 M $ 8.11 -1.44 % $ 219 M israelIsrael
Ardelyx Ardelyx
ARDX
71.8 M $ 6.32 -3.54 % $ 1.52 B usaUSA